IRD Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -187.51% compared to Opus Genetics's net margin of -49.65%. Opus Genetics's return on equity of -220.73% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Opus Genetics has a consensus price target of $6.00, signalling upside risk potential of 435.71%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Opus Genetics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Opus Genetics is more attractive than NovaBay Pharmaceuticals.

Opus Genetics has a beta of -0.018, which suggesting that the stock is 101.838% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Opus Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opus Genetics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Opus Genetics quarterly revenues are $4.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Opus Genetics's net income of -$8.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Opus Genetics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opus Genetics is 2.38x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -187.51% compared to Opus Genetics's net margin of --. Opus Genetics's return on equity of -220.73% beat Oragenics's return on equity of --.

Opus Genetics has a consensus price target of $6.00, signalling upside risk potential of 435.71%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Opus Genetics, analysts believe Oragenics is more attractive than Opus Genetics.

Opus Genetics has a beta of -0.018, which suggesting that the stock is 101.838% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Opus Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opus Genetics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Opus Genetics quarterly revenues are $4.4M, which are larger than Oragenics quarterly revenues of --. Opus Genetics's net income of -$8.2M is lower than Oragenics's net income of -$2.2M. Notably, Opus Genetics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opus Genetics is 2.38x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -187.51% compared to Opus Genetics's net margin of --. Opus Genetics's return on equity of -220.73% beat Theriva Biologics's return on equity of --.

Opus Genetics has a consensus price target of $6.00, signalling upside risk potential of 435.71%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Opus Genetics, analysts believe Theriva Biologics is more attractive than Opus Genetics.

Opus Genetics has a beta of -0.018, which suggesting that the stock is 101.838% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Opus Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opus Genetics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Opus Genetics quarterly revenues are $4.4M, which are larger than Theriva Biologics quarterly revenues of --. Opus Genetics's net income of -$8.2M is lower than Theriva Biologics's net income of -$4.3M. Notably, Opus Genetics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opus Genetics is 2.38x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology has a net margin of -187.51% compared to Opus Genetics's net margin of -6742.75%. Opus Genetics's return on equity of -220.73% beat Vir Biotechnology's return on equity of -45.02%.

Opus Genetics has a consensus price target of $6.00, signalling upside risk potential of 435.71%. On the other hand Vir Biotechnology has an analysts' consensus of $17.63 which suggests that it could grow by 225.79%. Given that Opus Genetics has higher upside potential than Vir Biotechnology, analysts believe Opus Genetics is more attractive than Vir Biotechnology.

Opus Genetics has a beta of -0.018, which suggesting that the stock is 101.838% less volatile than S&P 500. In comparison Vir Biotechnology has a beta of 1.224, suggesting its more volatile than the S&P 500 by 22.375%.

Opus Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opus Genetics pays -- of its earnings as a dividend. Vir Biotechnology pays out -- of its earnings as a dividend.

Opus Genetics quarterly revenues are $4.4M, which are larger than Vir Biotechnology quarterly revenues of $1.8M. Opus Genetics's net income of -$8.2M is higher than Vir Biotechnology's net income of -$121M. Notably, Opus Genetics's price-to-earnings ratio is -- while Vir Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opus Genetics is 2.38x versus 51.74x for Vir Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.